Curated peer-reviewed studies and clinical literature on Parkinson's disease — organized by topic, reviewed for accuracy, and explained in terms accessible to patients and caregivers without sacrificing scientific integrity.
A first-person account of surviving norovirus with Parkinson's disease — and why a 48-hour illness for most people becomes a week-long crisis for patients with PD. Covers the compounding effects of autonomic dysfunction, dehydration-driven neurological deterioration, the critical challenge of maintaining medication timing when unable to keep anything down, aspiration risk, emergency warning signs, and practical recovery guidance. Includes an important note for emergency providers on dopamine-blocking anti-nausea medications that must be avoided in Parkinson's patients.
This scoping review analyzed 10 studies (285 screened articles) examining HIIT across mild-to-moderate PD stages. HIIT administered 2–3 times weekly for 30–60 minutes over 8–12 weeks improved cardiorespiratory fitness, motor severity, and functional mobility, though gains were comparable to moderate-intensity continuous training rather than clearly superior. Neurobiological evidence suggests HIIT may support neuroprotection by increasing brain-derived neurotrophic factor levels and dopamine transporter uptake. Authors recommend individualized heart rate targets and perceived exertion for patients with autonomic dysfunction, and extended programs beyond 12 weeks to optimize outcomes.
This case-control study compared Mediterranean diet adherence in 257 PD patients versus 198 healthy controls using a standardized dietary questionnaire. Higher adherence to a Mediterranean-style diet was associated with reduced odds of Parkinson's disease after adjusting for age and caloric intake. Patients with lower diet adherence also experienced symptom onset at an earlier age, suggesting dietary patterns may influence both disease risk and the timing of symptom emergence.
A follow-up study of 84 patients who completed LSVT LOUD therapy found that patients who maintained daily practice retained 68% of vocal loudness gains at 24 months, compared to 31% in those who did not practice regularly. The study provides the strongest evidence to date that LSVT LOUD gains are durable with maintenance practice, and quantifies the benefit of adherence. Key implication: structured daily practice tools — even without live therapist contact — substantially extend therapeutic benefit.
The largest GWAS of Parkinson's disease to date, analyzing genomic data from over 400,000 individuals (49,000 PD cases), identified 78 novel risk loci — more than doubling the number of known genetic associations. The study implicates lysosomal dysfunction, mitochondrial quality control, and immune pathways as central to PD pathogenesis. Several identified genes are targets of compounds already in clinical development, accelerating drug discovery timelines.
A cross-sectional study of 312 PD caregiver–patient dyads found that non-motor symptoms — particularly cognitive decline, sleep disorders, and behavioral changes — accounted for more caregiver burden than motor disability alone. The findings challenge the prevailing focus on motor outcomes and argue for routine non-motor symptom assessment as a standard of care. Interventions targeting non-motor symptoms had larger effect sizes on caregiver quality of life than those targeting motor function.
The DYSCOVER trial compared continuous subcutaneous levodopa/carbidopa infusion to optimized oral therapy in 87 patients with advanced PD and motor fluctuations. The infusion group showed significantly greater reduction in "off" time (−2.72 hours/day, p<0.001), fewer dyskinesias, and improved patient-reported quality of life. The device was well-tolerated, with injection site reactions as the primary adverse event. Results support infusion therapy as a viable step-up from oral management in suitable patients.
This meta-analysis of 16 longitudinal studies (3,206 participants with isolated REM sleep behavior disorder) found a 10-year cumulative conversion rate to Parkinson's disease or related synucleinopathy of 73.5%. The analysis confirms RBD as the single strongest prodromal marker of PD currently known, with implications for early intervention trial design and neuroprotective strategies. Proposes a staging framework integrating RBD, anosmia, and constipation as preclinical Parkinson's syndrome.
A randomized crossover trial of 14 patients compared adaptive (closed-loop) DBS — which adjusts stimulation in real time based on local field potential biomarkers — to conventional continuous DBS. Adaptive DBS produced equivalent or superior motor outcomes with 38% less total stimulation charge delivered, translating to longer battery life and potentially fewer stimulation-related side effects. The study is a proof-of-concept milestone for next-generation neuromodulation in PD.
This study profiled the gut microbiome of 490 PD patients and 234 healthy controls across five sites. PD patients showed significant depletion of short-chain fatty acid-producing bacteria (particularly Faecalibacterium prausnitzii and Roseburia intestinalis) and enrichment of pro-inflammatory taxa. Microbiome composition was independently associated with non-motor symptom burden, constipation severity, and cognitive scores. The findings support the gut-brain axis hypothesis and suggest the gut microbiome as a potential therapeutic target.
ParkinsonLife accepts submissions from researchers, clinicians, and scientists working in the Parkinson's disease field. All submitted papers are reviewed for scientific quality before being listed. We particularly welcome contributions in under-represented areas: non-motor symptoms, caregiver outcomes, and health disparities in PD care.